Abstracts

PREDICTED LONG-TERM ADVERSE BIRTH AND CHILD HEALTH OUTCOMES IN THE ADVANCE TRIAL

First-line treatment with the integrase inhibitor dolutegravir (DTG) is associated with significant and progressive weight gain, especially among black women and if combined with TAF/FTC. If women become clinically obese after long-term treatment, this could increase risks of adverse birth and child health outcomes. This analysis assessed long-term risks of adverse outcomes in pregnancy and…

ANTIRETROVIRAL THERAPY CLASS AND GESTATIONAL WEIGHT GAIN: RESULTS FROM PHACS SMARTT

Excessive gestational weight gain (GWG) is associated with poor maternal, perinatal, and metabolic outcomes. In non-pregnant persons living with HIV (PLHIV), integrase inhibitors (INSTIs) are associated with greater weight gain compared to protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs). We evaluated the association of INSTI-based ART with GWG in pregnant PLHIV. The Surveillance…

CARDIOMETABOLIC HEALTH IN HIV+ AND HIV- PREGNANT SOUTH AFRICAN WOMEN

HIV and antiretroviral therapy (ART) frequently influences cardiometabolic health, including obesity, glucose metabolism, lipids, and blood pressure (BP), but there are few data on the cardiometabolic impact of HIV and ART in pregnancy. We consecutively enrolled HIV+ and HIV- women in routine antenatal care at 24-28 weeks’ gestation in Cape Town. At enrollment, women underwent…

ANTENATAL PROGESTERONE PROTECTS AGAINST FETAL GROWTH RESTRICTION IN WOMEN WITH HIV

Widespread use of antiretroviral therapy (ART) has substantially reduced vertical HIV transmission. Second-line ART regimens that include protease inhibitors (PI) have been linked to adverse pregnancy outcomes such as maternal preeclampsia (PEC) and fetal growth restriction. Progesterone supplementation reverses PI-associated placental angiogenic changes in mouse models. The Improving Pregnancy Outcomes with Progesterone (IPOP) trial was…

RISK STRATIFICATION FOR IDENTIFYING OPTIMAL TREATMENT DURATION IN ALL MDR-TB PATIENTS

Multidrug-resistant tuberculosis (MDR-TB) requires extensive chemotherapy, with up to 2 years of treatment with toxic drugs. Using pooled individual patient data, we aimed to identify patient phenotypes who require shorter or longer treatment durations to optimize their chances of cure. Published observational and experimental studies of MDR-TB treatment (12938 patients) were considered for analysis. Baseline…